中国骨质疏松杂志
中國骨質疏鬆雜誌
중국골질소송잡지
CHINESE JOURNAL OF OSTEOPOROSIS
2014年
5期
569-574
,共6页
活血化瘀%血瘀%骨质疏松症
活血化瘀%血瘀%骨質疏鬆癥
활혈화어%혈어%골질소송증
Activate blood and resolve stasis%Blood stasis%Osteoporosis
原发性骨质疏松症（ Primary Osteoporosis ，POP）是一种以骨量减少、骨强度下降、骨脆性增加及骨折危险性增大为特征的代谢性疾病，包括绝经后骨质疏松症（Postmenopausal Osteoporosis，PMOP）和老年性骨质疏松症（Senile Osteoporosis，SOP）。中医认为OP的发生与肾虚血瘀密切相关，补肾活血方药在治疗OP方面具有独特优势。然而，历代医家依据肾主骨理论辨证施治时大多偏重于使用补肾药，却忽视活血化瘀药物的应用，目前活血化瘀药物多作为配合应用，处于从属地位，研究提示活血化瘀中药治疗OP具有重要作用。本文就近年来活血化瘀法治疗OP的研究进展进行综述。
原髮性骨質疏鬆癥（ Primary Osteoporosis ，POP）是一種以骨量減少、骨彊度下降、骨脆性增加及骨摺危險性增大為特徵的代謝性疾病，包括絕經後骨質疏鬆癥（Postmenopausal Osteoporosis，PMOP）和老年性骨質疏鬆癥（Senile Osteoporosis，SOP）。中醫認為OP的髮生與腎虛血瘀密切相關，補腎活血方藥在治療OP方麵具有獨特優勢。然而，歷代醫傢依據腎主骨理論辨證施治時大多偏重于使用補腎藥，卻忽視活血化瘀藥物的應用，目前活血化瘀藥物多作為配閤應用，處于從屬地位，研究提示活血化瘀中藥治療OP具有重要作用。本文就近年來活血化瘀法治療OP的研究進展進行綜述。
원발성골질소송증（ Primary Osteoporosis ，POP）시일충이골량감소、골강도하강、골취성증가급골절위험성증대위특정적대사성질병，포괄절경후골질소송증（Postmenopausal Osteoporosis，PMOP）화노년성골질소송증（Senile Osteoporosis，SOP）。중의인위OP적발생여신허혈어밀절상관，보신활혈방약재치료OP방면구유독특우세。연이，역대의가의거신주골이론변증시치시대다편중우사용보신약，각홀시활혈화어약물적응용，목전활혈화어약물다작위배합응용，처우종속지위，연구제시활혈화어중약치료OP구유중요작용。본문취근년래활혈화어법치료OP적연구진전진행종술。
The primary osteoporosis ( POP) is a metabolic disorder of the skeleton characterized by reduced bone mass, decreased bone strength, and increased bone fragility and fracture risks, including the postmenopausal osteoporosis ( PMOP) and the senile osteoporosis ( SOP) .TCM believes that the pathogenesis of osteoporosis is deeply related to kidney deficiency and blood stasis. There is a unique advantage in the treatment of osteoporosis using the kidney nourishing and blood activating herbs.However, according to the theory of the kidney governing the bone, most TCM physicians extremely emphasize on the application of nourishing kidney herbs while ignore the use of blood circulation herbs.At present, promoting blood circulation therapy is a subordinate treatment.More and more researches suggest that the blood-activating and stasis-resolving herb plays an important role in the treatment of osteoporosis.This paper reviews the research progress about blood-activating and stasis-resolving therapy in the treatment of osteoporosis in recent years.
